|
시장보고서
상품코드
2091947
키너렛(Kineret) 시장 규모, 점유율 및 성장 분석 : 적응증별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Kineret Market Size, Share, and Growth Analysis, By Indication, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 키너렛(Kineret) 시장 규모는 2024년에 51억 5,000만 달러로 평가되며, 2025년 57억 7,000만 달러에서 2033년까지 142억 9,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 12.0%로 성장할 것으로 전망되고 있습니다.
전 세계 키너렛 시장에서는 주로 류마티스 관절염 및 특정 자가면역 질환의 치료에 사용되는 재조합 인간 인터류킨-1 수용체 길항제인 아나킨라에 대한 견고한 수요가 나타나고 있습니다. 그 매력은 표적을 정확히 겨냥한 작용 기전에 있으며, 이는 일반적인 면역억제제와는 확연히 차별화되어 치료적 가치를 높여줍니다. 이 약제는 관절의 염증과 통증을 완화하는 효과 외에도, 전신성 소아 특발성 관절염 및 성인 발병형 스틸병 등의 적응증에 대한 최근 적응증 확대로 인해 시장에서 입지를 크게 넓히고 있습니다. 주요 촉진요인으로는 사이토카인 관련 질환의 유병률 상승, 보다 안전한 생물제제에 대한 수요, 그리고 류마티스 관절염 환자 수 증가에 기여하는 고령화 등을 들 수 있습니다. 이러한 요인들은 키너렛의 빈번한 사용을 촉진할 뿐만 아니라, 보험 환급과 관련된 지원 정책의 수립도 지원하여, 궁극적으로 매출을 끌어올리고 있습니다. 특히 최근 연구에서는 COVID-19와 관련된 과도한 염증에 대처하는 데 있으며, 키너렛의 잠재력이 강조되고 있으며, 그 적용 범위는 더욱 다양해지고 있습니다.
세계 키너렛 시장의 성장 요인
세계 키너렛 시장의 주요 성장 동인 중 하나는 류마티스 관절염이나 스틸병과 같은 자가면역 질환 및 염증성 질환의 유병률 증가입니다. 이러한 만성질환의 부담 증가는 효과적인 치료법에 대한 수요를 촉진하고 있으며, 키너렛은 치료 요법에서 중요한 역할을 담당하고 있습니다. 또한 염증 반응 관리에 있으며, IL-1 수용체 길항제의 이점에 대한 의료 종사자와 환자들의 인식이 높아지고 있는 점도 시장 확대에 기여하고 있습니다. 키너렛의 치료 적응증 확대 및 투여 방법 개선을 목표로 한 지속적인 연구개발 노력은 해당 시장의 잠재력을 한층 더 높여주고, 전 세계 환자들의 접근성을 향상시키고 있습니다.
세계 키너렛 시장의 제약 요인
세계 키너렛 시장의 주요 시장 제약 요인 중 하나는 높은 치료비입니다. 이로 인해 환자의 접근성이 제한되고, 시장 전체의 보급률이 낮아질 가능성이 있습니다. 류마티스 관절염이나 자가염증성 질환 등의 치료에 사용되는 생물제제인 키너렛은, 약제 자체뿐만 아니라 관련 의료 서비스에도 막대한 비용이 드는 경우가 많습니다. 이러한 경제적 부담으로 인해 환자들은 더 저렴한 대체 치료법을 선택하거나 치료 자체를 포기할 가능성이 있으며, 이는 시장 성장을 저해할 우려가 있습니다. 또한 보험 적용 범위의 제한과 보험 환급과 관련된 문제들이 치료 접근성을 더욱 복잡하게 만들고 있으며, 키너렛 시장의 확장에 있으며, 중대한 장벽이 되고 있습니다.
세계 키너렛 시장의 동향
전 세계 키너렛 시장에서는 면역 조절 작용을 입증하는 새로운 임상적 근거에 힘입어, 맞춤형 면역 요법으로의 뚜렷한 추세가 나타나고 있습니다. 이 접근 방식은 개별화된 바이오마커 프로파일을 통합함으로써 치료 효과를 높이는 동시에 잠재적인 부작용을 최소화하고 있습니다. 의료 종사자들은 개별 환자의 필요에 맞춰 투여 일정과 병용 요법 프로토콜을 점점 더 세밀하게 조정함으로써, 특정 질환의 특성에 부합하는 치료 성과를 최적화하고 있습니다. 그 결과, 키너렛을 맞춤형 치료 요법에 포함시키는 것이 점점 더 보편화되고 있으며, 이는 환자별 반응을 우선시하는 맞춤형 의료 솔루션으로의 광범위한 전환을 반영하는 것으로, 키너렛은 향후 치료 전략에서 중요한 역할을 수행하게 될 것입니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 키너렛 시장 규모 : 적응증별
세계의 키너렛 시장 규모 : 유통 채널별
세계의 키너렛 시장 규모 : 최종사용자별
세계의 키너렛 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Kineret Market size was valued at USD 5.15 Billion in 2024 and is poised to grow from USD 5.77 Billion in 2025 to USD 14.29 Billion by 2033, growing at a CAGR of 12.0% during the forecast period (2026-2033).
The global Kineret market showcases a robust demand for Anakinra, a recombinant human interleukin-1 receptor antagonist, primarily used for rheumatoid arthritis and select autoimmune disorders. Its appeal stems from its targeted mechanism, distinguishing it from generic immune suppressants and enhancing its therapeutic value. The drug's market presence has expanded significantly due to its efficacy in alleviating joint inflammation and pain, alongside recent label expansions for conditions like systemic juvenile idiopathic arthritis and adult-onset Still's disease. Key drivers include the rising prevalence of cytokine-related diseases, the demand for safer biological treatments, and an aging population contributing to increased rheumatoid arthritis cases. These factors not only promote frequent Kineret utilization but also foster the development of supportive insurance reimbursement policies, ultimately boosting sales. Notably, emerging research underscores Kineret's potential in addressing COVID-19-related hyper-inflammation, further diversifying its application scope.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Kineret market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Kineret Market Segments Analysis
Global kineret market is segmented by indication, distribution channel, end user and region. Based on indication, the market is segmented into Rheumatoid Arthritis (RA), Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Cold Autoinflammatory Syndrome (FCAS), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Gouty Arthritis and Other Indications. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals & Clinics, Homecare Settings and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Kineret Market
One of the key market drivers for the Global Kineret Market is the increasing prevalence of autoimmune diseases and inflammatory disorders, such as rheumatoid arthritis and Still's disease. This rising burden of chronic conditions has stimulated demand for effective therapeutic options, positioning Kineret as a crucial player in treatment regimens. Additionally, growing awareness among healthcare professionals and patients regarding the benefits of IL-1 receptor antagonists in managing inflammatory responses contributes to market expansion. Continued research and development efforts aimed at expanding the therapeutic indications and improving the delivery methods of Kineret further enhance its market potential and accessibility to patients worldwide.
Restraints in the Global Kineret Market
One key market restraint for the global Kineret market is the high cost of therapy, which may limit patient access and reduce overall market penetration. Kineret, a biologic treatment for conditions such as rheumatoid arthritis and autoinflammatory diseases, often comes with significant expenses related to both the medication itself and the associated healthcare services. This financial burden can lead to patients opting for alternative, less costly treatments or forgoing therapy altogether, potentially stifling market growth. Additionally, insurance coverage limitations and reimbursement challenges further complicate accessibility, making it a critical hurdle for expanding the Kineret market reach.
Market Trends of the Global Kineret Market
The Global Kineret market is witnessing a significant trend towards personalized immunotherapy, driven by new clinical evidence showcasing its immune-modulating properties. This approach integrates personalized biomarker profiles to enhance treatment efficacy while minimizing potential side effects. Healthcare professionals are increasingly fine-tuning dosing schedules and combination protocols tailored to individual patient needs, thereby optimizing therapeutic outcomes aligned with specific disease characteristics. As a result, the incorporation of Kineret into personalized treatment regimens is becoming more prevalent, reflecting a broader shift toward customized healthcare solutions that prioritize patient-specific responses, making Kineret a key player in future therapeutic strategies.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Kineret Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Rheumatoid Arthritis (RA)
- Cryopyrin-Associated Periodic Syndromes (CAPS)
- Familial Cold Autoinflammatory Syndrome (FCAS)
- Systemic Juvenile Idiopathic Arthritis (sJIA)
- Adult-Onset Still's Disease (AOSD)
- Gouty Arthritis
- Other Indications
Global Kineret Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Kineret Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals & Clinics
- Homecare Settings
- Specialty Clinics
Global Kineret Market Size & CAGR (2026-2033)
- North America (Indication, Distribution Channel, End User)
- US
- Canada
- Europe (Indication, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Swedish Orphan Biovitrum AB (Sobi)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RocheHolding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kedrion Biopharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CSL Behring LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSD (Merck Sharp & Dohme)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novacyt S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ViroGates A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Handok Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
